CD47 blockade with PARP inhibition for disease treatment
AssigneePfizer Inc.
InventorsLisa Danae Schultz Johnson, Lei Cui
Life of this patent
Estimating the term…
Abstract
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRPαFc. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgG1 or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.
Claims13
A method for treating a subject presenting with CD47+ disease cells, comprising administering to the subject a PARP inhibitor and a CD47 blocking agent in combination with radiation therapy, wherein the CD47 blocking agent is a CD47-binding SIRPα polypeptide and wherein the CD47-binding SIRPα polypeptide is an Fc fusion protein comprising a CD47-binding region of soluble human SIRPα.
Dependencies are inferred from the claim text.